Product Details
| Product Name:
Delamanid |
CAS No.:
681492-22-8 |
| Purity:
99.98% |
Supply Ability:
10g |
| Release date:
2025/05/16 |
Product Introduction
Bioactivity
| Name | Delamanid |
| Description | Delamanid (OPC-67683) is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall. |
| Kinase Assay | In a 200 μL reaction volume, 1 μM TEM-1 is incubated with and without 5 μM Avibactam for 5 min at 37°C and subjected to two ultrafiltration cartridge (UFC) steps to remove excess inhibitor (Ultrafree-0.5 with Biomax membrane, 5-kDa cutoff). Centrifugation at 10,600× g for 8 min is performed at 4°C. After each ultrafiltration step, 20 μL retentate is diluted with 180 μL assay buffer to restore the original enzyme concentration. After two UFC treatments, the amount of free Avibactam is quantified by LC/MS/MS and found to be <5% of the original concentration. Loss of protein during UFC is assessed by measuring TEM-1 activity (on 4,000-fold dilution) in the acyl-enzyme sample compare with a non-UFC-treated enzyme, and loss is found to be <5%[1]. |
| In vitro | In vitro: inhibits the synthesisi of mucolic acids, cruciala component of the cell wall of the Mycobacterium tuberculosis complex.[1] In in-vitro studies, delamanid shows more potent antibacterial activity against drug-susceptible and drug-resistant strains of M. tuberculosis.[2] Delamanid do not affect rifampin, pyrazinamide, and isoniazid exposure; the ethambutol AUCτ and Cmax values are about 25% higher with delamanid coadministration. |
| In vivo | In vivo: Twice-daily oral dosing of delamanid at 30 mg kg-1 for 5 days resulted in sterile cures in a mouse model of VL. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (93.55 mM), Sonication is recommended.
|
| Keywords | OPC67683 | OPC 67683 | Inhibitor | inhibit | Delamanid | Bacterial | Anti-infection | Antiinfection | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Doxycycline (hyclate) | Kanamycin sulfate | Urethane | Sulfamethoxazole sodium | Doxycycline | EDTA copper(II) disodium salt | Isoeugenol | Dimethyl sulfoxide |
| Related Compound Libraries | Bioactive Compound Library | Pediatric Drug Library | Approved Drug Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Bacterial Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:146032-79-3
$49.00 / 1mg
-
CAS:531-29-3
$98.00 / 1mg
-
CAS:1123-95-1
$94.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$0.00/10mg |
VIP1Y
|
Moxin Chemicals
|
2025-02-27 |
|
|
$0.00/1kg |
|
Nanjing Fred Technology Co., Ltd
|
2023-12-29 |
|
|
$6.68/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-08 |
United States